VG20 Stock Overview
A commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Avinger, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.43 |
| 52 Week High | US$21.15 |
| 52 Week Low | US$5.40 |
| Beta | 1.29 |
| 11 Month Change | 0% |
| 3 Month Change | 0.56% |
| 1 Year Change | -68.52% |
| 33 Year Change | -91.04% |
| 5 Year Change | -99.26% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| VG20 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.4% | -0.4% |
| 1Y | -68.5% | -7.1% | 7.1% |
Return vs Industry: VG20 underperformed the German Medical Equipment industry which returned -2.5% over the past year.
Return vs Market: VG20 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| VG20 volatility | |
|---|---|
| VG20 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 5.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: VG20 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine VG20's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 73 | Jeff Soinski | avinger.com |
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company’s lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, including Ocelot and Tigereye, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients.
Avinger, Inc. Fundamentals Summary
| VG20 fundamental statistics | |
|---|---|
| Market cap | €4.02m |
| Earnings (TTM) | -€17.29m |
| Revenue (TTM) | €7.20m |
0.6x
P/S Ratio-0.2x
P/E RatioIs VG20 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VG20 income statement (TTM) | |
|---|---|
| Revenue | US$7.75m |
| Cost of Revenue | US$5.44m |
| Gross Profit | US$2.31m |
| Other Expenses | US$20.92m |
| Earnings | -US$18.61m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -13.58 |
| Gross Margin | 29.84% |
| Net Profit Margin | -240.18% |
| Debt/Equity Ratio | -1,018.8% |
How did VG20 perform over the long term?
See historical performance and comparison